News FDA panel narrowly backs heart benefit of BI/Lilly diabetes ... FDA advisers voted 12-11 that Jardiance also reduces cardiovascular risks.
News Sanofi and BI finalise swap to create market leading consume... Sanofi and BI finalise CHC and animal health swap
News Victoza disappoints on cardio benefits, lifts rival Jardianc... Victoza results are significant, but fell short of investors' expectations.
News Lily gets FDA nod for SERD-CDK 4/6 combo in breast cancer Eli Lilly's imlunestrant (Inluriyo) for breast cancer has received a new FDA approval, in combination with CDK4/6 inhibitor abemaciclib (Verzenio).
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
